Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px
Employment/Membership › Details

Proteome Sciences–Söhngen M: management, 202009– CEO before Convert Pharmaceuticals + Mologen + Paion


Period Period 2020-09-15
  Predecessor Convert Pharmaceuticals–Söhngen M: management, 201811– CEO before Mologen + Paion
Organisations Organisation Proteome Sciences plc
  Organisation 2 Convert Pharmaceuticals S.A.
Product Product  proteomics
Person Person Söhngen, Mariola (Proteome Sciences 202009– CEO before Convert Pharmaceuticals + Mologen + Paion)

Proteome Sciences plc. (9/14/20). "Press Release: Appointment of Chief Executive Officer".

The Board of Proteome Sciences plc is pleased to announce that Dr. Mariola Söhngen has been appointed as a director and Chief Executive Officer and she will take up the position on September 15th, 2020. Dr Ian Pike remains a director of the Company as Chief Scientific Officer, having also fulfilled the role of Interim Chief Executive Officer until Dr Söhngen’s appointment.

Dr. Söhngen has established a strong and successful career in the pharmaceutical industry bothin the US and Europe. She was a co-founder of Paion AG which developed a clinical-stage asset for the treatment of stroke and subsequently delivered a novel anaesthetic that received FDA approval earlier this year. Dr. Söhngen was instrumental in the acquisition of UK listed CeNeS Pharmaceuticals plc by Paion AG. Dr. Söhngen has also held roles as CEO at Mologen AG and Convert Pharmaceuticals and most recently rana pharmaceutical consultancy with a strong focus on supporting Chinese companies and investors trying to enter the European pharmaceuticals research and development market.

Proteome Sciences Chairman Christopher Pearce commented “The Board is delighted to appoint Dr. Mariola Söhngen as our new CEO where she will build on the strong foundations that have already been established. Mariola’s time as Chief Medical Officer at Paion together with her international experience and network will bring major benefits to our business as we look to engage more broadly with new and existing clients in the US, Europe and to address the rapidly growing Asian markets.”

Commenting on her appointment, Dr. Söhngen said “I am very much looking forward to working with the highly respected and committed team at Proteome Sciences. The company has established a unique position in Precision Medicine through its specialist services business and the range of TMT® and TMTpro™ chemical tags sold globally by Thermo Scientific. I am excited to work with the board to expand commercial activities and continue to develop the corporate strategy. From my involvement in stroke at Paion, I arrive at the company highly impressed withthe quality of the Proteome Sciences’ technology in particular the biomarker discovery capabilities in Precision Medicine and Diagnostics which are of ever-increasing importance and value in these challenging times. As CEO of Proteome Sciences I look forward to applying the broad experience gained from my previous interactions with a wide range of pharmaceutical companies to strengthen Proteome Sciences ´ position in Precision Medicine and to drive shareholder value.”

Pursuant to Schedule 2 (g) of the AIM Rules for Companies, Dr. Mariola Gabriela Söhngen (aged 59) has held the following directorships or partnerships in the past five years:


Dres. Söhngen Beteiligungs GmbH


PAION Deutschland GmbH
PAION Holdings UK Limited
PAION UK Limited
Vita 34AG
Mologen AG
Convert Pharmaceuticals SA

For further information:

Proteome Sciences plc
Dr Ian Pike, Interim Chief Executive Officer
Richard Dennis, Chief Commercial Officer
Tel: +44 (0)20 7043 2116

Allenby Capital Limited (AIM Nominated Adviser & Broker)

John Depasquale / Jeremy Porter (Corporate Finance)
Tony Quirke (Sales)
Tel: +44 (0) 20 3328 5656

About Proteome Sciences plc. (

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discoveryof disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.

Record changed: 2020-11-20


Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Proteome Sciences (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81

» top